We focus on FDA-approved GLP-1 care pathways.
How do I get co-pay assistance or reimbursement for a GLP-1?
This is a payment modifier: it applies inside whichever coverage situation you're in.
The answer routes entirely on what coverage you have — and the good news is that the main form of “assistance” applies instantly at the pharmacy counter rather than through claim forms you file later.
Commercial insurance that covers the drug: enroll in the manufacturer’s savings card — Wegovy and Ozempic through NovoCare, Zepbound and Mounjaro through Lilly. Each brings the copay to as little as $25 per fill, applied when the prescription is processed. The catch is the caps: monthly savings limits (typically $100–$150) mean a very high copay won’t always reach the $25 floor.
Medicare, Medicaid, TRICARE, or VA: savings cards are excluded by law on all government coverage — no exceptions. The main cost path is Medicare’s GLP-1 Bridge: a $50/month copay for certain GLP-1s through December 31, 2027, if you have Part D and meet the BMI criteria. Beyond that, your plan’s formulary decides — our coverage-and-appeals guide covers what to do when a prior authorization is denied.
No coverage: manufacturer patient assistance programs provide certain medications free to eligible lower-income patients, but read the medication lists carefully — Lilly Cares currently lists Trulicity (not Zepbound or Mounjaro), and Novo Nordisk’s program covers Ozempic (not Wegovy). The published self-pay prices on our pricing page are the fallback floor.
On true reimbursement — paying first and claiming money back — the manufacturer programs don’t generally work that way; they discount at the point of sale. If you paid out of pocket while a coverage decision was pending, that conversation is with your insurer, and an approved appeal is the usual basis for it.